REG - Hikma Pharmaceutical - Holding(s) in Company <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

03/07/2017 15:05

RNS Number : 9623J
Hikma Pharmaceuticals Plc
03 July 2017
Notification of major interests in shares
LONDON, 3 July 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:
1
Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached
Hikma Pharmaceuticals PLC
2
Reason for the notification


An acquisition or disposal of voting rights
Yes

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached
No

An event changing the breakdown of voting rights
No

Other (please specify): Compliance with the Transparency Directive
No
3
Full name of the person subject to the notification obligation
The Capital Group Companies, Inc.
4
Full name of shareholders 
Refer to section 9 
5
Date of the Transaction (and date on which the threshold crossed is reached differently)
27 June 2017
6
Date on which the issuer notified
3 July 2017 (sent 28 June 2017)
7
Threshold that is crossed
Above 10%
8
Notified details
See A, B & C below



A. Voting rights attached to shares
Class type of shares (if possible using the ISIN code)
Situation previous to the triggering transaction
Resulting situation after the triggering transaction
Number of shares
Number of voting rights
Number of shares
Number of voting rights
% of voting rights
Direct
Direct
Indirect
Direct 
Indirect
Ordinary Shares (0.10 GBP)
GB00B0LCW083
22,012,431
22,012,431


24,331,416

10.1151%
B. Qualifying Financial instruments
Resulting situation after the triggering transaction
Type of financial instrument
Expiration Date
Exercise/Conversion Period/Date
Number of voting rights that may be acquired if the instrument if exercised/converted
% of voting rights
-
-
-
-
-
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument
Exercise Price
Expiration Date
Exercise/Conversion Period/Date
Number of voting rights instrument refers to
% of voting rights
Nominal 
Delta
-
-
-
-
-
-
-
Total A+B+C
Number of Voting rights
% of voting rights
24,331,416
10.1151%
9
Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable


Number of
Shares
Percent of Outstanding
The Capital Group Companies, Inc. ("CG") holdings
24,331,416
10.1151%




Holdings by CG Management Companies and Funds:


 Capital Research and Management Company
24,331,416
10.1151%
Proxy Voting
10
Name of the proxy holder
N/A
11
Number of voting rights proxy holder will cease to hold:

12
Date on which proxy holder will cease to hold voting rights:

13
Additional Information

14
Contact name:
Christopher Aquino
15
Contact telephone number:
+001 (213) 615-0469
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
HOLUORSRBRABRAR